NLRP3 and colorectal carcinoma: In CRC patients, tumoral Fn/Pg burden could inform prognostic stratification and guide eligibility for trials targeting microbial–immune axes (e.g., FadA/gingipains, NLRP3/TLR4–NF-κB).